CL2009000453A1 - Composicion farmaceutica que comprende i) compuesto derivado triciclico nitrogenado, tal como pirido[2,3-b]indol, ii) al menos un derivado de ciclodextrina y iii) agua, util para prevenir o tratar cancer e inflamacion, entre otras; metodo para mejorar la solubilidad y estabilidad en agua de dichos compuestos. - Google Patents

Composicion farmaceutica que comprende i) compuesto derivado triciclico nitrogenado, tal como pirido[2,3-b]indol, ii) al menos un derivado de ciclodextrina y iii) agua, util para prevenir o tratar cancer e inflamacion, entre otras; metodo para mejorar la solubilidad y estabilidad en agua de dichos compuestos.

Info

Publication number
CL2009000453A1
CL2009000453A1 CL2009000453A CL2009000453A CL2009000453A1 CL 2009000453 A1 CL2009000453 A1 CL 2009000453A1 CL 2009000453 A CL2009000453 A CL 2009000453A CL 2009000453 A CL2009000453 A CL 2009000453A CL 2009000453 A1 CL2009000453 A1 CL 2009000453A1
Authority
CL
Chile
Prior art keywords
water
pyrido
indole
inflammation
iii
Prior art date
Application number
CL2009000453A
Other languages
English (en)
Inventor
Futo Tomomichi
Nakai Shinichiro
Laurentius De Jong Rinaldo
Lee Bumsup
Joseph Christopher Ronald
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40560232&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000453(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2009000453A1 publication Critical patent/CL2009000453A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Composición farmacéutica que comprende i) compuesto de fórmula i derivado de triciclos nitrogenados, tal como pirido[2,3-b]indol, ii) al menos un derivado de ciclodextrina y iii) agua, útil para prevenir o tratar cáncer, inflamación, psoriasis, entre otras; método para mejorar la solubilidad en agua de dichos compuestos.
CL2009000453A 2008-02-28 2009-02-27 Composicion farmaceutica que comprende i) compuesto derivado triciclico nitrogenado, tal como pirido[2,3-b]indol, ii) al menos un derivado de ciclodextrina y iii) agua, util para prevenir o tratar cancer e inflamacion, entre otras; metodo para mejorar la solubilidad y estabilidad en agua de dichos compuestos. CL2009000453A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3216508P 2008-02-28 2008-02-28

Publications (1)

Publication Number Publication Date
CL2009000453A1 true CL2009000453A1 (es) 2010-08-13

Family

ID=40560232

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000453A CL2009000453A1 (es) 2008-02-28 2009-02-27 Composicion farmaceutica que comprende i) compuesto derivado triciclico nitrogenado, tal como pirido[2,3-b]indol, ii) al menos un derivado de ciclodextrina y iii) agua, util para prevenir o tratar cancer e inflamacion, entre otras; metodo para mejorar la solubilidad y estabilidad en agua de dichos compuestos.

Country Status (22)

Country Link
US (1) US20100331357A1 (es)
EP (1) EP2252291A1 (es)
JP (1) JP2011513201A (es)
KR (1) KR20100129308A (es)
CN (1) CN102014901A (es)
AR (1) AR071354A1 (es)
AU (1) AU2009217969A1 (es)
BR (1) BRPI0908077A2 (es)
CA (1) CA2716720A1 (es)
CL (1) CL2009000453A1 (es)
CO (1) CO6290659A2 (es)
CR (1) CR11660A (es)
DO (1) DOP2010000262A (es)
EA (1) EA201071007A1 (es)
EC (1) ECSP10010505A (es)
IL (1) IL207734A0 (es)
MA (1) MA32165B1 (es)
MX (1) MX2010009513A (es)
PE (1) PE20091432A1 (es)
TW (1) TW200938544A (es)
WO (1) WO2009107877A1 (es)
ZA (1) ZA201006224B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827307B (zh) * 2011-06-17 2015-06-17 首都医科大学 β-环糊精修饰的四氢-β-咔啉羧酸衍生物及其制备方法和应用
CN103450371A (zh) * 2012-06-01 2013-12-18 首都医科大学 四氢-β-咔啉-3-甲酰基-二乙烯三胺-β-环糊精，其制备，抗血栓活性和应用
CA2878500A1 (en) * 2012-07-12 2014-01-16 Sanofi Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
AU2015301054B2 (en) 2014-08-08 2020-05-14 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JP2017155023A (ja) * 2016-03-04 2017-09-07 ジェイファーマ株式会社 Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP1903039A4 (en) * 2005-06-13 2010-09-22 Takeda Pharmaceutical INJECTION
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors

Also Published As

Publication number Publication date
TW200938544A (en) 2009-09-16
CA2716720A1 (en) 2009-09-03
ECSP10010505A (es) 2010-10-30
KR20100129308A (ko) 2010-12-08
DOP2010000262A (es) 2010-09-30
EP2252291A1 (en) 2010-11-24
JP2011513201A (ja) 2011-04-28
MA32165B1 (fr) 2011-03-01
PE20091432A1 (es) 2009-10-17
AR071354A1 (es) 2010-06-16
EA201071007A1 (ru) 2011-04-29
CO6290659A2 (es) 2011-06-20
US20100331357A1 (en) 2010-12-30
BRPI0908077A2 (pt) 2015-08-25
WO2009107877A1 (en) 2009-09-03
MX2010009513A (es) 2010-09-22
IL207734A0 (en) 2010-12-30
CR11660A (es) 2010-11-25
ZA201006224B (en) 2011-11-30
CN102014901A (zh) 2011-04-13
AU2009217969A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
PE20160588A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
WO2009111676A8 (en) Boron-containing small molecules as anti-inflammatory agents
EA201290389A8 (ru) Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
UY30051A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
ECSP088871A (es) Derivados de triazolopirazina
UY32147A (es) Derivados de indol y de indolina y métodos para usarlos
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
BRPI0511132A (pt) derivados de pirimidina e composição farmacêutica compreendendo os mesmos
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
NI200900219A (es) DERIVADOS DE BENCIMIDAZOL Caso: PC 33611A
EA200601766A1 (ru) Производные имидазола
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
CO6290654A2 (es) Derivados de salinosporamida como inhibidores de proteasoma
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201101180A1 (ru) Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы
PA8779101A1 (es) "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
DOP2011000153A (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para el uso en el trata miento del cancer
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
CL2009000453A1 (es) Composicion farmaceutica que comprende i) compuesto derivado triciclico nitrogenado, tal como pirido[2,3-b]indol, ii) al menos un derivado de ciclodextrina y iii) agua, util para prevenir o tratar cancer e inflamacion, entre otras; metodo para mejorar la solubilidad y estabilidad en agua de dichos compuestos.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)